Pfizer Inc. (NYSE:PFE) Announces Q3 2025 Dividend

Pfizer Inc. (NYSE:PFE) is one of the top cheap pharmaceutical stocks to buy now. On June 25, Pfizer Inc. (NYSE:PFE) announced that its board of directors approved a $0.43 Q3 2025 dividend on the company’s common stock, payable September 2, 2025, to holders of the Common Stock of record at the close of business on July 25, 2025. The Q3 2025 cash dividend marks Pfizer Inc.’s (NYSE:PFE) 347th consecutive quarterly dividend.

Pfizer’s (PFE) Breakthrough Medicines Power its Dividend Stability

A medical technician wearing protective gloves and a mask mixing a biopharmaceutical solution.

Pfizer Inc. (NYSE:PFE) reported in its fiscal Q1 2025 results that the first phase of its manufacturing optimization program is on track to deliver around $1.5 billion in net cost savings by the end of 2026, with initial savings expected in the second half of 2025.

Pfizer Inc. (NYSE:PFE) also reaffirmed all components of its full-year 2025 financial guidance. It expects revenues to be in the $61 billion to $64 billion range and adjusted diluted EPS in the $2.80 to $3.00 range.

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that manufactures, develops, markets, and sells biopharmaceutical products worldwide. It advances wellness, prevention, treatment, and cures in developing and emerging markets.

While we acknowledge the potential of PFE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PFE and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.